Previous 10 | Next 10 |
home / stock / jnj / jnj articles
On Tuesday, Johnson & Johnson (NYSE:JNJ) announced results from a prespecified second interim analysis of Phase 3 CARTITUDE-4 study evaluating...
A New Jersey federal judge has dismissed a lawsuit brought by a Johnson & Johnson (NYSE:JNJ) subsidiary against Dr. Jacqueline Moline, who publ...
A federal judge has denied a group of cancer victims’ request to halt Johnson & Johnson (NYSE:JNJ) from moving forward with a proposed ba...
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneousl...
Sanofi SA (NASDAQ:SNY) is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considerin...
The U.S. Supreme Court has supported 21 pharmaceutical and medical equipment companies, led by AstraZeneca Plc (NYSE:AZN), in a lawsuit accusing th...
For Immediate Release Chicago, IL – June 21, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the ...
Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...
Johnson & Johnson (NYSE:JNJ) is reportedly facing a new proposed class action lawsuit seeking damages and medical monitoring for women who have...
News, Short Squeeze, Breakout and More Instantly...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 05:40:00 ET On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare c...